Furthermore, treatment with first-line disease-modifying therapies DMTs such as glatiramer acetate (GA) and interferon-beta (IFNβ) is associated with increased IL-10 production by PBMCs isolated from EAE mice and MS patients (61, 62, 69, 70). This evidence concerns the gene IFNB1 and myeloid sarcoma.